828 Prolonged Regression of Ileocolonic Crohn's Disease Following Autologous Haemopoetic Stem Cell Transplantation: Presentation on Behalf of the Astic Trialists

TNF-naive and -failure subgroups. Adverse events were comparable across treatment groups; serious adverse events were more common in the eldelumab 10 and 20 mg/kg groups (7.5% and 9.8%, respectively) compared with placebo (5.0%), driven by infusion-related events. Rates of infection were similar across all groups. Conclusion: Induction treatment with eldelumab 10 or 20 mg/kg IV demonstrated trends towards efficacy as assessed by both clinical and endoscopic endpoints. Safety signals were consistent with those reported previously for eldelumab.1,2 1. Sandborn WJ, et al. Gastroenterology 2014;146(Suppl 1):S-55. 2. Mayer L, et al. Gut 2014;63:442-50. Clinical efficacy